Research Group
Lania Group
Cellular and Molecular Endocrinology Lab
Cellular and Molecular Endocrinology Lab research is mainly focused on the pathogenesis of endocrine tumors (mainly pituitary and neuroendocrine tumors) and the mechanisms involved in determining the sensitivity of these tumors to medical treatment. The Research activity is strictly linked to the Clinical activity of both Pituitary Unit and ENETS Multidisciplinary group on Neuroendocrine Tumors at Humanitas Research Hospital.
Actually Lab’s activity is focusing on:
the impact of cytoskeleton manipulation on Neuroendocrine tumorigenesis
the intracellular interplay of different drugs in the control of neuroendocrine tumor proliferation
the role of tumor microenvironment in the control of NET progression and response to medical treatment
Selected publications
Cytoskeleton Protein Filamin A Is Required for Efficient Somatostatin Receptor Type 2 Internalization and Recycling through Rab5 and Rab4 Sorting Endosomes in Tumor Somatotroph Cells.
cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression.
Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors.
Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.
Dopamine receptor type 2 (DRD2) inhibits migration and invasion of human tumorous pituitary cells through ROCK-mediated cofilin inactivation.
cAMP effects in neuroendocrine tumors: The role of Epac and PKA in cell proliferation and adhesion.
Different expression of protein kinase A (PKA) regulatory subunits in normal and neoplastic thyroid tissues.
Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells.
Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy.
d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.
Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients.
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.
Effect of 9-cis retinoic acid on dopamine D2 receptor expression in pituitary adenoma cells.
High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells.
Effect of cyclic adenosine 3′,5′-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas.
Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein.
Group members
